Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

430.19 -4.12 (-0.95%)
Streaming Delayed Price Updated: 11:44 AM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Vertex to Participate in Upcoming May Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports First Quarter 2026 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Announce First Quarter 2026 Financial Results on May 4th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
Via ACCESS Newswire
News headline image
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in Upcoming March Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
Issued on behalf of Avant Technologies Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports Third Quarter 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in the UBS Global Healthcare Conference on November 11
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces Key Advancements Across Kidney Portfolio
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
From Vertex Pharmaceuticals
Via Business Wire
News headline image
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in Upcoming September Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports Second Quarter 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.